<!-- STATUS: RECOVERED-FROM-DB | UPDATED: 2026-09-12 | ep17_medicare-part-d -->
# Facts recovered from blackbox.db (MCP return timed out; ingest succeeded)

- **blackbox row id:** 37230
- **ts:** 2026-09-12T19:43:07
- **domain:** political
- **state:** flagged
- **model_used:** l1_l2_admit:63f546fb0f3e
- **confidence:** None
- **source:** None

## Query
What is the annual federal cost of the Medicare Part D prescription drug program?

## Result (verbatim from brain)
The annual **federal cost** of Medicare Part D (the prescription drug benefit) refers specifically to the net outlays made by the U.S. federal government to fund the program, excluding beneficiary premiums, state contributions (for dual-eligible beneficiaries), and other non-federal funding sources. This cost is primarily driven by federal subsidies for beneficiary premiums, reinsurance payments for high-cost drugs, and low-income subsidy (LIS) payments.

Based on the most recent official data from the **2023 Medicare Trustees Report** (which covers actual spending through 2022):

- **Federal outlays for Medicare Part D in 2022 were approximately $122 billion**.  
  This figure represents the net federal expenditure after accounting for:
  - Beneficiary premiums paid directly to plans (which offset federal costs).
  - State contributions for dual-eligible beneficiaries (those qualifying for both Medicare and Medicaid).
  - Other minor adjustments.

### Important Context & Projections:
1. **Growth Trend**: Part D costs have risen steadily since its inception in 2006 due to increased enrollment, higher drug utilization, and specialty drug price growth. Federal spending was ~$60 billion in 2010 and has nearly doubled since.
2. **Future Projections** (per CBO and Trustees Reports):
   - The Congressional Budget Office (CBO) projects federal Part D spending to reach **~$150 billion by 2025** and **exceed $200 billion by 2030** under current law.
   - These projections *partially* incorporate the Inflation Reduction Act (IRA) of 2022, which includes provisions allowing Medicare to negotiate certain drug prices (starting in 2026), cap insulin costs, and penalize price inflation above inflation. The CBO estimates the IRA’s drug pricing provisions will reduce federal Part D spending by **~$100 billion over 10 years (2023–2032)**, though savings will phase in gradually.
3. **What’s Included in Federal Cost**:
   - **Direct Subsidies**: Federal government pays ~74.5% of the base beneficiary premium (varies by plan).
   - **Reinsurance**: Covers 80% of drug costs above the catastrophic threshold (after beneficiary pays 5% coinsurance).
   - **Low-Income Subsidy (LIS)**: Fully covers premiums and cost-sharing for eligible low-income beneficiaries (about 20% of Part D enrollees).
   - *Excluded*: Beneficiary-paid premiums (~25.5% of base premium), state payments for dual eligibles, and beneficiary out-of-pocket costs (deductibles, copays).

### Sources:
- [2023 Medicare Trustees Report, Table II.B5](https://www.cms.gov/files/document/2023-medicare-trustees-report.pdf) (Actual 2022 federal outlays: $122.0 billion).
- [CBO Baseline Projections for Medicare, May 2023](https://www.cbo.gov/publication/59130) (Part D outlays projected at $148B in 2025, $205B in 2030).
- [CBO Cost Estimate for the Inflation Reduction Act, August 2022](https://www.cbo.gov/publication/58501) (Estimates IRA savings for Part D).

### Key Takeaway:
While the **most recent completed year (2022)** saw **$122 billion in federal spending**, current policy and demographic trends indicate this cost is growing rapidly and is projected to surpass **$150 billion annually by mid-decade**. The IRA’s drug negotiation provisions are expected to moderate this growth over time, but significant federal expenditure will persist due to an aging population and innovative (often high-cost) therapies.

For real-time tracking, the [CMS Medicare Program Statistics](https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats) and [Monthly Treasury Statements](https://fiscal.treasury.gov/reports-statements/mts/) provide updated data, but official annual figures are finalized in the Trustees Report each spring.

## Provenance
none